Literature DB >> 30446942

A high titer of acquired factor V inhibitor in a hemodialysis patient who developed arterial thrombosis.

Hina Ogawa1, Masayoshi Souri2,3,4, Kazunori Kanouchi2,5, Tsukasa Osaki2,3,4, Rie Ohkubo1, Tomoko Kawanishi1, Sachiko Wakai1, Keita Morikane2,5, Akitada Ichinose6,7.   

Abstract

An 87-year-old man with diabetes mellitus was admitted to control recurrent bleeding from hemodialysis puncture sites. He was a smoker and had been diagnosed with arteriosclerosis obliterans. His PT and APTT were markedly prolonged, and all coagulation factors were markedly decreased (factor V [FV] activity < 1%) or below the measurement threshold, with the exception of fibrinogen and factor XIII. Neither PT nor APTT were corrected upon mixing with normal plasma. A high titer of FV inhibitor was found at 415 BU/mL, and anti-FV autoantibody was detected by both immunoblot assay and ELISA. Prednisolone administration and plasma exchange partially improved prolonged PT and APTT and decreased the FV inhibitor level. Five months later, he manifested symptoms of severe ischemia in both legs. Angiography revealed diffuse stenosis downstream of both common iliac arteries. Endovascular therapy was repeated four times, the prednisolone dose was reduced, and low-dose antiplatelet therapy was initiated. After the final successful endovascular therapy, arterial thrombosis was detected using ultrasound and angiography. Aspiration thrombectomy and thrombolytic therapy failed to achieve recanalization, and necrosis of the legs worsened. Despite the severe coagulation abnormalities, vascular interventions should have been performed with regular-dose antiplatelet therapy, as the patient exhibited multiple risk factors for atherothrombosis.

Entities:  

Keywords:  Anti-factor V autoantibody; Bleeding/hemorrhage; False multiple factor deficiencies; False multiple factor inhibitors; Thrombosis

Mesh:

Substances:

Year:  2018        PMID: 30446942     DOI: 10.1007/s12185-018-2561-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  21 in total

Review 1.  Clinical and laboratory manifestations of anti-factor V antibodies.

Authors:  T L Ortel
Journal:  J Lab Clin Med       Date:  1999-04

Review 2.  Acquired factor V inhibitors.

Authors:  P Knöbl; K Lechner
Journal:  Baillieres Clin Haematol       Date:  1998-06

Review 3.  Acquired factor V inhibitor after exposure to topical human thrombin related to an otorhinolaryngological procedure.

Authors:  K Donohoe; R Levine
Journal:  J Thromb Haemost       Date:  2015-09-30       Impact factor: 5.824

4.  Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation.

Authors:  Emmanuel J Favaloro; Jennifer Posen; Raj Ramakrishna; Soma Soltani; Simon McRae; Sarah Just; Margaret Aboud; Joyce Low; Rosalie Gemmell; Geoff Kershaw; Robyn Coleman; Mark Dean
Journal:  Blood Coagul Fibrinolysis       Date:  2004-10       Impact factor: 1.276

5.  Deep vein thrombosis associated with factor V inhibitor followed by immune thrombocytopenia.

Authors:  Takakazu Higuchi; Takeshi Okamoto; Toshiyuki Kou; Tadashi Takeuchi; Ryosuke Koyamada; Sadamu Okada
Journal:  Ann Hematol       Date:  2012-05-16       Impact factor: 3.673

Review 6.  Acquired hemophilia.

Authors:  L N Boggio; D Green
Journal:  Rev Clin Exp Hematol       Date:  2001-12

7.  Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.

Authors:  Peter W Collins; Sybil Hirsch; Trevor P Baglin; Gerard Dolan; John Hanley; Michael Makris; David M Keeling; Ri Liesner; Simon A Brown; Charles R M Hay
Journal:  Blood       Date:  2006-10-17       Impact factor: 22.113

8.  Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations.

Authors:  Michael Kalafatis; Paolo Simioni; Daniela Tormene; Daniel O Beck; Sonia Luni; Antonio Girolami
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

Review 9.  Acquired factor V inhibitor. A problem-based systematic review.

Authors:  Ai Leen Ang; Ponnudurai Kuperan; Chin Hin Ng; Heng Joo Ng
Journal:  Thromb Haemost       Date:  2009-05       Impact factor: 5.249

10.  Acquired factor V inhibitor in a patient with mantle cell lymphoma presenting with hematuria followed by thrombosis: a case report.

Authors:  Naif I Aljohani; John H Matthews
Journal:  Int Med Case Rep J       Date:  2014-02-24
View more
  4 in total

1.  Acquired factor V inhibitors after allogeneic hematopoietic stem cell transplantation in a dog.

Authors:  Joseph Masciana; Nathan Peterson; John Chretin
Journal:  J Vet Intern Med       Date:  2020-07-20       Impact factor: 3.333

2.  Autoimmune Factor V Deficiency That Took 16 Years to Diagnose due to Pseudodeficiency of Multiple Coagulation Factors.

Authors:  Takaaki Kato; Takaya Hanawa; Mea Asou; Tomohiko Asakawa; Hisashi Sakamaki; Makoto Araki
Journal:  Case Rep Med       Date:  2021-01-12

3.  Acquired factor V inhibitor with erythema and eosinophilia in a patient with end-stage renal disease.

Authors:  Eisuke Katsuren; Kentaro Kohagura; Takanori Kinjyo; Ryo Zamami; Takuto Nakamura; Nanako Oshiro; Yoshitsugu Sunagawa; Kumiko Omine; Yuki Kudo; Yuki Shinzato; Tsukasa Osaki; Masayoshi Souri; Akitada Ichinose; Masanobu Yamazato; Akio Ishida; Yusuke Ohya
Journal:  CEN Case Rep       Date:  2022-08-09

4.  Acquired Factor V Inhibitor Complicated with Immune Thrombocytopenia.

Authors:  Fuka Mima; Ryota Minami; Mizuki Asako; Hitomi Matsunaga; Yuri Fujita; Yoshimi Takimoto; Sonoko Senda; Wataru Nakahara; Mako Ikeda; Shuji Ueda
Journal:  Intern Med       Date:  2021-06-26       Impact factor: 1.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.